|
Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Genentech; Medivation/Astellas |
|
|
Travel, Accommodations, Expenses - General electric systems; Siemens Healthcare Diagnostics; Varian Medical Systems; ViewRay |
|
|
Other Relationship - NRG Oncology |
|
|
Consulting or Advisory Role - Blue Earth Diagnostics; GenomeDx; Laguna Pharmaceutical (I) |
Research Funding - Janssen |
Patents, Royalties, Other Intellectual Property - UpToDate |
Other Relationship - Algeta ASA; Medivation; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Medivation |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Augmenix |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
Consulting or Advisory Role - GenomeDx |
|
Research Funding - GenomeDx; Medivation/Astellas |
Travel, Accommodations, Expenses - GenomeDx |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - UpToDate Editor |
|
|
Honoraria - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |